High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids

References

• Tworoger SS, Shafrir AL, Hankinson SE. Ovarian cancer. Schottenfeld Fraumeni Cancer Epidemiol. 2017;384(9951):889–908. Prev. Fourth Ed
   Google Scholar
• Asai A, Okita T, Enzo A. Conflicting messages concerning current strategies against research misconduct in Japan: a call for ethical spontaneity. J Med Ethics. 2016;42(8):524–527. doi:10.1001/jama.2017.21421.
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–725. doi:10.1038/nrc3144.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10(4):211–224. doi:10.1038/nrclinonc.2013.5.
   PubMed Web of Science ®Google Scholar
• Zurawski VR, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988;42(5):677–680. doi:10.1002/ijc.2910420507.
   PubMed Web of Science ®Google Scholar
• Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22(20):4059–4066. doi:10.1200/JCO.2004.03.091JCO.2004.03.091.
   PubMed Web of Science ®Google Scholar
• Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC, Davis G, Serra S, Diamandis EP, Kulasingam V. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2016;25(9):1333–1340. doi:10.1158/1055-9965.EPI-15-1299.
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402–408. doi:10.1016/j.ygyno.2007.10.017.
   PubMed Web of Science ®Google Scholar
• Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn. 2016;16(8):811–826. doi:10.1080/14737159.2016.1194758.
   PubMed Web of Science ®Google Scholar
• Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trends Cancer. 2017;3(3):198–213. doi:10.1016/j.trecan.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Zaenker P, Gray ES, Ziman MR. Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev. 2016;15(5):477–483. doi:10.1016/j.autrev.2016.01.017.
   PubMed Web of Science ®Google Scholar
• Kobold S, Lütkens T, Cao Y, Bokemeyer C, Atanackovic D. Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol. 2010;71(7):643–651. doi:10.1016/j.humimm.2010.03.015.
   PubMed Web of Science ®Google Scholar
• Reuschenbach M, Von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58(10):1535–1544. doi:10.1007/s00262-009-0733-4.
   PubMed Web of Science ®Google Scholar
• Shi JX, Qin JJ, Ye H, Wang P, Wang KJ, Zhang JY. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: A systematic review with meta-analysis. Expert Rev Mol Diagn. 2015;15(6):829–852. doi:10.1586/14737159.2015.1035713.
   PubMed Web of Science ®Google Scholar
• Fortner RT, Damms-Machado A, Kaaks R. Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017;147(2):465–480. doi:10.1016/j.ygyno.2017.07.138.
   PubMed Web of Science ®Google Scholar
• Lacombe J, Mangé A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, Maudelonde T, Solassol J. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer. 2013;132:1105–1113. doi:10.1002/ijc.27766.
   PubMed Web of Science ®Google Scholar
• Hirales Casillas CE, Flores Fernández JM, Camberos EP, Herrera López EJ, Pacheco GL, Velázquez MM. Current status of circulating protein biomarkers to aid the early detection of lung cancer. Futur Oncol. 2014;10(8):1501–1513. doi:10.2217/fon.14.21.
   PubMed Web of Science ®Google Scholar
• Hong Y, Huang J. Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. World J Hepatol. 2015;7(11):1581–1585. doi:10.4254/wjh.v7.i11.1581.
   PubMed Web of Science ®Google Scholar
• Werner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015;136(10):2243–2252. doi:10.1002/ijc.28807.
   PubMed Web of Science ®Google Scholar
• Chen H, Werner S, Tao S, Zörnig I, Brenner H. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett. 2014;346(2):178–187. doi:10.1016/j.canlet.2014.01.007.
   PubMed Web of Science ®Google Scholar
• Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do K-A, Kim J, Troncoso P, Logothetis CJ, Sidman RL, et al. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci. 2015;112(8):2515–2520. doi:10.1073/pnas.1500097112.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Ritter E, Buchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zornig I, Chen Y-T, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci. 2010;107(11):5088–5093. doi:10.1073/pnas.0914213107.
   PubMed Web of Science ®Google Scholar
• Stafford P, Cichacz Z, Woodbury NW, Johnston SA. Immunosignature system for diagnosis of cancer. Proc Natl Acad Sci. 2014;111(30):E3072–E3080. doi:10.1073/pnas.1409432111.
   PubMed Web of Science ®Google Scholar
• Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res. 2008;14(3):764–771. doi:10.1158/1078-0432.CCR-07-0856.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006;66(2):1181–1190. doi:10.1158/0008-5472.CAN-04-2962.
   PubMed Web of Science ®Google Scholar
• Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273–282. doi:10.1038/nrc3432.
   PubMed Web of Science ®Google Scholar
• Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics. 2009;8(4):661–669. doi:10.1074/mcp.M800313-MCP200.
   PubMed Web of Science ®Google Scholar
• Martin K, Ricciardelli C, Hoffmann P, Oehler MK. Exploring the immunoproteome for ovarian cancer biomarker discovery. Int J Mol Sci. 2011;12(1):410–428. doi:10.3390/ijms12010410.
   PubMed Web of Science ®Google Scholar
• Huang H, Li Y, Liu J, Zheng M, Feng Y, Hu K, Huang Y, Huang Q. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One. 2012;7(12):e51256. doi:10.1371/journal.pone.0051256.
   PubMed Web of Science ®Google Scholar
• Bery A, Leung F, Smith CR, Diamandis EP, Kulasingam V. Deciphering the ovarian cancer ascites fluid peptidome. Clin Proteomics. 2014;11(1):13. doi:10.1186/1559-0275-11-13.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu B, Liu Y, Yao H, Lu N, Li B, Gao J, Guo S, Han N, Qi J, et al. The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers. Proteomics. 2012;12(11):1883–1891. doi:10.1002/pmic.201100654.
   PubMed Web of Science ®Google Scholar
• Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, Meri S. Ascitic complement system in ovarian cancer. Br J Cancer. 2005;92(5):895–905. doi:10.1038/sj.bjc.6602334.
   PubMed Web of Science ®Google Scholar
• Heegaard NHH, West-Nørager M, Tanassi JT, Houen G, Nedergaard L, Høgdall C, Høgdall E. Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival. PLoS One. 2012;7(2). doi:10.1371/journal.pone.0030997.
   PubMed Web of Science ®Google Scholar
• Chan CP, Kok KH, Jin DY. CREB3 subfamily transcription factors are not created equal: recent insights from global analyses and animal models. Cell Biosci. 2011;1(1):6. doi:10.1186/2045-3701-1-6.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Yoshida H. TFE3, HSP47, and CREB3 pathways of the mammalian golgi stress response. Cell Struct Funct. 2017;42(1):27–36. doi:10.1247/csf.16023.
   PubMed Web of Science ®Google Scholar
• Carim-Todd L, Sumoy L, Andreu N, Estivill X, Escarceller M. Cloning, mapping and expression analysis of C15 or f4, a novel human gene with homology to the yeast mitochondrial ribosomal protein Yml30 gene. Mitochondrial DNA. 2001;12(2):91–96. doi:10.3109/10425170109047561.
   Web of Science ®Google Scholar
• Brown A, Amunts A, Bai XC, Sugimoto Y, Edwards PC, Murshudov G, Scheres SHW, Ramakrishnan V. Structure of the large ribosomal subunit from human mitochondria. Science. 2014;346(6210):718–722. doi:10.1126/science.1258026.
   PubMed Web of Science ®Google Scholar
• Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A. 2002;99(11):7444–7449. doi:10.1073/pnas.062189599.
   PubMed Web of Science ®Google Scholar
• Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164(5):1060–1072. doi:10.1016/j.cell.2016.01.015.
   PubMed Web of Science ®Google Scholar
• Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000;14(14):1810–1823. doi:10.1111/j.1754-7121.1984.tb00653.x.
   PubMed Web of Science ®Google Scholar
• Martínez de Paz A, Ausió J; HMGNs. The enhancer charmers. BioEssays. 2016;38(3):226–231. doi:10.1002/bies.201500157.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Lin CH, Jan YH, Su CY, Yao YC, Cheng HC, Hsu TI, Wang PS, Su WP, Yang CJ, et al. Huntingtin-interacting protein-1 is an early-stage prognostic biomarker of lung adenocarcinoma and suppresses metastasis via AKT-mediated epithelial-mesenchymal transition. Am J Respir Crit Care Med. 2016;193(8):869–880. doi:10.1164/rccm.201412-2226OC.
   PubMed Web of Science ®Google Scholar
• Porpaczy E, Bilban M, Heinze G, Gruber M, Vanura K, Schwarzinger I, Stilgenbauer S, Streubel B, Fonatsch C, Jaeger U. Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12. Eur J Clin Invest. 2009;39(7):568–575. doi:10.1111/j.1365-2362.2009.02146.x.
   PubMed Web of Science ®Google Scholar
• Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, Ahmad S, Radhakrishnan A, Barbhuiya MA, Kumar RV, et al. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta - Proteins Proteomics. 2013;1834(11):2308–2316. doi:10.1016/j.bbapap.2013.04.029.
   Web of Science ®Google Scholar
• Yang Q, Bavi P, Wang JY, Roehrl MH. Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases. J Proteomics. 2017;168:53–65. doi:10.1016/j.jprot.2017.06.021.
   PubMed Web of Science ®Google Scholar
• Di Niro R, Sulic AM, Mignone F, D’Angelo S, Bordoni R, Iacono M, Marzari R, Gaiotto T, Lavric M, Bradbury ARM, et al. Rapid interactome profiling by massive sequencing. Nucleic Acids Res. 2010;38(9). doi:10.1093/nar/gkq052
   PubMed Web of Science ®Google Scholar
• Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G, et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database. 2013;2013. doi:10.1093/database/bat013.
   PubMedGoogle Scholar
• Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256. doi:10.3389/fonc.2013.00256.
   PubMedGoogle Scholar
• Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics. 2005;5(17):4625–4636. doi:10.1002/pmic.200401321.
   PubMed Web of Science ®Google Scholar
• Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St.Onge P, Kireeva I, Schmitt-Ulms G, Brown TJ, Murphy J, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res. 2008;7(1):339–351. doi:10.1021/pr0703223.
   PubMed Web of Science ®Google Scholar
• Gunawardana CG, Memari N, Diamandis EP. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. Clin Biochem. 2009;42(4–5):426–429. doi:10.1016/j.clinbiochem.2008.11.008.
   PubMed Web of Science ®Google Scholar
• Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Trope CG, Berner A, Ec K. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res. 2006;12(3I):791–799. doi:10.1158/1078-0432.CCR-05-2516.
   PubMed Web of Science ®Google Scholar
• Staals RH, Pruijn GJ. The human exosome and disease. Adv Exp Med Biol. 2011;702:132–142.
   PubMed Web of Science ®Google Scholar
• Shiba N, Yoshida K, Shiraishi Y, Okuno Y, Yamato G, Hara Y, Nagata Y, Chiba K, Tanaka H, Terui K, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol. 2016;175(3):476–489. doi:10.1111/bjh.14247.
   PubMed Web of Science ®Google Scholar
• Garziera M, Montico M, Bidoli E, Scalone S, Sorio R, Giorda G, Lucia E, Toffoli G. Prognostic role of serum antibody immunity to p53 oncogenic protein in ovarian cancer: a systematic review and a meta-analysis. PLoS One. 2015;10(10). doi:10.1371/journal.pone.0140351.
   Web of Science ®Google Scholar
• Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, et al. Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer. Clin Cancer Res. 2017;23(19):5912–5922. doi:10.1158/1078-0432.CCR-17-0284.
   PubMed Web of Science ®Google Scholar
• Kaaks R, Fortner RT, Hüsing A, Barrdahl M, Hopper M, Johnson T, Tjønneland A, Hansen L, Overvad K, Fournier A, et al. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. Int J Cancer. 2018;143(3):515–526. doi:10.1002/ijc.31335.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Tainsky MA. Autoantibodies as biomarkers for ovarian cancer. Cancer Biomarkers. 2010;8(4–5):187–201. doi:10.3233/CBM-2011-0213.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–1388. doi:10.1016/S0140-6736(13)62146-7.
   PubMed Web of Science ®Google Scholar
• Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14(4):1065–1072. doi:10.1158/1078-0432.CCR-07-1569.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010;10(3):321–328. doi:10.1586/erm.10.12.
   PubMed Web of Science ®Google Scholar
• Di Niro R, D’Angelo S, Secco P, Marzari R, Santoro C, Sblattero D. Profiling the autoantibody repertoire by screening phage-displayed human cDNA libraries. Methods Mol Biol. 2009;570:353–369. doi:10.1007/978-1-60327-394-7_20.
   PubMedGoogle Scholar
• Musgrove AJ, Austin GE, Hearn RD, Holt CA, Stroud DA, Wotton SR. Overwinter population estimates of British waterbirds. Br Birds. 2011;104(7):364–397. doi:10.1016/j.jconrel.2016.07.053.
   Web of Science ®Google Scholar
• Deantonio C, Sedini V, Cesaro P, Quasso F, Cotella D, Persichetti F, Santoro C, Sblattero D. An Air-well sparging minifermenter system for high-throughput protein production. Microb Cell Fact. 2014;13(1). doi:10.1186/s12934-014-0132-1.
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Mignone F, Deantonio C, Di Niro R, Bordoni R, Marzari R, De Bellis G, Not T, Ferrara F, Bradbury A, et al. Profiling celiac disease antibody repertoire. Clin Immunol. 2013;148(1):99–109. doi:10.1016/j.clim.2013.04.009.
   PubMed Web of Science ®Google Scholar